Taysha Gene Therapies Engages Talent with Stock Options
Taysha Gene Therapies, Inc. (NASDAQ: TSHA), a biotechnology company currently in the clinical stage, has recently taken a notable step to strengthen its team by offering stock options to a new employee. This initiative is part of the company’s strategic commitment to advancing adeno-associated virus (AAV)-based gene therapies that target severe monogenic diseases affecting the central nervous system.
Details of the Stock Options Granted
On a recent date, Taysha's Compensation Committee granted an option for 311,000 shares of common stock to the newly hired team member. This decision aligns with the Taysha Gene Therapies, Inc. 2023 Inducement Plan and adheres to Nasdaq Listing Rule 5635(c)(4), which permits such grants as part of the hiring process.
Stock Option Specifications
The stock option features an exercise price of $2.06 per share, which corresponds to the closing price of Taysha's stock on the day the grant was made. These options are set for a 10-year term and will vest over a four-year period. Initially, 25% of the options will become available after one year, while the remaining 75% will vest monthly over the subsequent three years. It’s important to note that continued employment at Taysha is necessary for the options to vest.
About Taysha Gene Therapies
Taysha Gene Therapies (NASDAQ: TSHA) is focused on creating transformative medicines for individuals suffering from severe neurological conditions. One of its leading clinical programs is TSHA-102, which aims to address Rett syndrome, a rare neurodevelopmental disorder. Currently, there are no approved therapies that tackle the underlying genetic causes of this condition, underscoring Taysha's crucial role in bridging this gap.
Focus on Transformative Healthcare
With a strong commitment to gene therapy, Taysha utilizes advanced manufacturing techniques and a proven AAV9 capsid to efficiently translate research findings into effective treatments. The company is motivated by the urgent need to meet significant unmet medical needs, striving to make a meaningful impact on the lives of patients and their families.
Experienced Leadership Team
Taysha Gene Therapies is supported by a management team with extensive experience in the gene therapy sector. This expertise is essential as the company navigates the intricate landscape of drug development and commercialization strategies. Taysha is dedicated to pushing the limits of what is possible in the biomedical field, aiming for breakthroughs that can expand therapeutic options for many.
Continual Innovation in Gene Therapy
The company places a strong emphasis on innovation, investing in research that lays the groundwork for future therapies. By surrounding itself with talented individuals capable of driving advancements, Taysha positions itself at the forefront of gene therapy development.
Contact Information
For more information about Taysha Gene Therapies, please reach out to Hayleigh Collins, the Director and Head of Corporate Communications and Investor Relations at Taysha. You can contact her via email at hcollins@tayshagtx.com.
Frequently Asked Questions
What is Taysha Gene Therapies focused on?
Taysha Gene Therapies is dedicated to developing AAV-based gene therapies for severe monogenic diseases, particularly those affecting the central nervous system.
What was the recent stock option grant about?
The company granted stock options to a new employee as part of its induction process, allowing them to purchase 311,000 shares at $2.06 each.
How does the stock option vesting work?
The stock options vest over four years, with 25% becoming available after the first year and the remaining 75% vesting monthly over the following three years, contingent on continued employment.
What is TSHA-102?
TSHA-102 is Taysha's lead program under development to treat Rett syndrome, a rare neurodevelopmental disorder that currently lacks disease-modifying therapies.
Who's the contact for investor inquiries?
Hayleigh Collins is the Director of Corporate Communications and Investor Relations at Taysha and can be contacted at hcollins@tayshagtx.com.
